A Phase 1/2 interventional study of Datopotamab Deruxtecan (Dato-DXd) in Carcinoma, Non-Small-Cell Lung and Triple Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 21 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.
Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 1/2, reaches primary completion later than 0 of the 18 other live ones, and was the 10th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Taiwan
Ages 18+
AstraZeneca · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Latin American Cooperative Oncology Group · Sites in Brazil
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 16 more countries
Ages 18+
By country, each count listing its studies:
datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, datopotamab deruxtecan is the treatment under test here. Read study by study →
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 9
First in 2018; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 278 across the 21 interventional studies. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 75th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2022, is one of 10 in phase 1/2, reaches primary completion later than 13 of the 77 other live ones, and was the 160th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05687266Phase 3AstraZenecaPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment. The cancer may also be "metastatic", which means that it has spread to other parts of the body or the surrounding tissue.
The study drug, Datopotamab deruxtecan, is designed to work by attaching to the tumor cells and stopping the tumor growth. Datopotamab deruxtecan is also known as Dato-DXd.
In this study, the researchers want to find out how well Dato-DXd works to stop tumors from growing in Chinese participants with NCSLC or TNBC. This is the first time Dato-DXd is being studied in Chinese population.
Participants in this study will get Dato-DXd through a needle as an injection. They will get 1 dose of Dato-DXd every 3 weeks until their cancer gets worse or they leave the study for another reason.
Participants will visit their study sites at least once every 3 weeks for as long as they are in the study. The study doctors will take blood samples every 3 weeks and take images of the participants' tumors every 6 weeks until the participant leaves the study.
This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.
This study is divided into different cohorts. Participants of the same cohort are with the same tumour type. The starting cohorts are Cohort 1 (NSCLC) and Cohort 2 (TNBC). Future cohorts will consist of other advanced or metastatic solid tumour types, including, but not limited to, advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma or urothelial carcinoma that is refractory or intolerant to SoC therapy or for which no Standard of Care therapy is available.
Cohort 1 and Cohort 2 will be prioritised for immediate enrolment and the protocol will be amended as needed for the future cohorts.
Cohort 1: The target population of Cohort 1 is adult Chinese participants with advanced or metastatic NSCLC with or without actionable genomic alterations(AGAs) (ie, alterations in genes with approved therapies, such as EGFR, ALK, or other known AGAs).
Eligible participants without AGAs will have been previously treated with platinum-based chemotherapy and anti-PD-1/anti-PD-L1 monoclonal antibody either in combination or sequentially. Participants without AGAs who received anti-PD-1/anti-PD-L1 monoclonal antibody as frontline therapy may have received the combination of platinum-based chemotherapy and anti-PD-1/anti-PD-L1 monoclonal antibody in the second-line setting.
Eligible participants with AGAs will have been previously treated with one or two prior lines of applicable targeted therapy that is approved for the participant's genomic alteration and platinum-based chemotherapy as the only prior line of cytotoxic therapy. Participants with AGAs may have received up to one anti-PD-1/anti-PD-L1 monoclonal antibody treatment alone or in combination with chemotherapy.
A total of approximately 40 eligible participants in China will be enrolled in this cohort, including approximately 6 participants with AGAs.
Cohort 2: The target population of Cohort 2 is adult Chinese participants with inoperable locally advanced or metastatic TNBC who have received at least 2 prior chemotherapy regimens for advanced breast cancer, counting the (neo)adjuvant therapy as a prior chemotherapy regimen if progression occurred within 12 months after completion of the therapy (DFI ≤ 12 months).
A total of approximately 78 eligible participants in China will be enrolled in this cohort. Cohort 2 will enroll at most around 20% (approximately N=15) of enrolled participants with a DFI ≤ 12 months.
Enrolled participants will be treated with Dato-DXd at 6.0 mg/kg via an IV infusion on Day 1,every 3 weeks.
The primary objective of the study is to estimate the effectiveness of Dato-DXd by assessment of confirmed ORR by independent central review.
Key Inclusion Criteria:
Additional Inclusion Criteria for Cohort 1 (NSCLC):
- or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV NSCLC disease at the beginning of study intervention.
For the subset of participants without AGAs:
For the subset of participants with AGAs:
- Documented positive test results for one or more actionable genomic alteration: EGFR, ALK, ROS1, METex14 skipping, RET or other AGAs with approved therapies
- Received one or two prior lines of applicable targeted therapy for the participant's genomic alteration at the time of screening.
Additional Inclusion Criteria for Cohort 2 (TNBC)
Key Exclusion Criteria:
Additional Exclusion Criteria for Cohort 1 (NSCLC):
- Has mixed SCLC and NSCLC histology.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This single-arm study consists of multiple cohorts, divided by indication.
Drug: Datopotamab Deruxtecan (Dato-DXd)
Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
Also known as: DS-1062a
Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)
Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Confirmed Objective Response Rate(ORR) Assessed by Investigator
Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as determined by investigator assessment per RECIST 1.1.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Duration of Response (DoR), Assessed by Investigator
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investgator, or death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Disease Control Rate (DCR), Assessed by ICR
Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Best Overall Response (BoR) , Assessed by ICR
Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Time To Response (TTR) , Assessed by ICR
Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Progression-Free Survival (PFS) , Assessed by ICR
Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Overall Survival (OS)
Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Progression-Free Survival (PFS) , Assessed by Investigator
Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by investigator, or death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Disease Control Rate (DCR), Assessed by Investigator
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investigator, or death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Best Overall Response (BoR) , Assessed by Investigator
Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Time To Response (TTR) , Assessed by Investigator
Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody
PK parameters of Total Anti-TROP2 Antibody\_Area under the curve
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody
PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd
PK parameters of Dato-DXd\_Area under the curve
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd
PK parameters of Dato-DXd\_Maximum observed concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a
PK parameters of MAAA-1181a\_Area under the curve
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a
PK parameters of MAAA-1181a\_Maximum observed concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody
PK parameters of Total Anti-TROP2 Antibody\_Time to maximum plasma concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd
Time to maximum plasma concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a
PK parameters of MAAA-1181a\_Time to maximum plasma concentration
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Immunogenicity of Dato-DXd
The prevalence of ADA (positive at any visit)
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Duration of Response (DoR), Assessed by ICR
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by ICR, or death due to any cause.
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China. For TNBC cohort, first participant was screened on 11Jul2022, last participant was screened on 27Apr2023. For NSCLC cohort, first participant was screened on 29Aug2022, last participant was screened on 21Mar2023.
| Milestone | Dato-DXd_NSCLC | Dato-DXd_TNBC |
|---|---|---|
| Started | 40 | 79 |
| Completed | 13 | 29 |
| Not completed | 27 | 50 |
| Withdrew: Death | 27 | 43 |
| Withdrew: Lost to follow-up | 0 | 7 |
Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.
| Percentage of participants | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR) | 33.8 (23.4 to 45.4) | 45.0 (29.3 to 61.5) |
Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as determined by investigator assessment per RECIST 1.1.
| Percentage of participants | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Confirmed Objective Response Rate(ORR) Assessed by Investigator | 31.2 (21.1 to 42.7) | 32.5 (18.6 to 49.1) |
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investgator, or death due to any cause.
| months | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Duration of Response (DoR), Assessed by Investigator | 5.8 (4.01 to 8.4) | 8.1 (4.2 to 11.2) |
Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR
| Percentage | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Disease Control Rate (DCR), Assessed by ICR | 72.7 (61.4 to 82.3) | 85 (70.2 to 94.3) |
Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.
| Percentage | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Confirmed Partial Response | 33.8 | 45.0 |
| Confirmed Complete Response | 0 | 0 |
Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Time To Response (TTR) , Assessed by ICR | 1.5 (1.3 to 2.8) | 1.4 (1.3 to 2.7) |
Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Progression-Free Survival (PFS) , Assessed by ICR | 5.3 (4.2 to 6.9) | 8.0 (5.7 to 10.8) |
Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Overall Survival (OS) | 13.5 (10.7 to NA) | 16.7 (13.8 to 20.4) |
Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by investigator, or death due to any cause.
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Progression-Free Survival (PFS) , Assessed by Investigator | 4.3 (4.0 to 5.6) | 7.0 (5.5 to 9.5) |
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investigator, or death due to any cause.
| Percentage | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Disease Control Rate (DCR), Assessed by Investigator | 76.6 (65.6 to 85.5) | 85.0 (70.2 to 94.3) |
Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.
| Percentage | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Confirmed complete response | 0 | 0 |
| Confirmed partial response | 31.2 | 32.5 |
Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Time To Response (TTR) , Assessed by Investigator | 1.4 (1.4 to 1.6) | 1.4 (1.3 to 1.4) |
PK parameters of Total Anti-TROP2 Antibody\_Area under the curve
| day*ug/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody | 713.9 ± 25.45 | 569.3 ± 24.47 |
PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration
| ug/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody | 151.1 ± 11.62 | 115.5 ± 22.99 |
PK parameters of Dato-DXd\_Area under the curve
| day*ug/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd | 668.3 ± 21.11 | 504.5 ± 22.38 |
PK parameters of Dato-DXd\_Maximum observed concentration
| ug/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd | 150.9 ± 12.73 | 108.7 ± 11.30 |
PK parameters of MAAA-1181a\_Area under the curve
| day*ng/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a | 17.60 ± 24.64 | 17.66 ± 33.09 |
PK parameters of MAAA-1181a\_Maximum observed concentration
| ng/mL | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a | 2.976 ± 25.84 | 2.231 ± 27.51 |
PK parameters of Total Anti-TROP2 Antibody\_Time to maximum plasma concentration
| Hour | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody | 4.87 (1.55 to 7.17) | 1.58 (1.38 to 6.83) |
Time to maximum plasma concentration
| h | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd | 4.95 (1.83 to 7.17) | 1.63 (1.38 to 5.22) |
PK parameters of MAAA-1181a\_Time to maximum plasma concentration
| Hour | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a | 6.09 (4.87 to 24.22) | 22.52 (6.85 to 25.07) |
The prevalence of ADA (positive at any visit)
| percentage | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Immunogenicity of Dato-DXd | 33.3 | 36.8 |
Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by ICR, or death due to any cause.
| Month | TNBC Cohort | NSCLC Cohort |
|---|---|---|
| Duration of Response (DoR), Assessed by ICR | 6.7 (4.53 to 12.6) | 8.3 (5.9 to 9.4) |
Collected over Adverse Events had a median follow-up of 6.13 months for NSCLC cohort and 4.99 months for TNBC cohort. All-Cause Mortality was assessed from enrollment to 13 months post last subject dose with a median of 12 months follow up for the TNBC cohort, and from enrollment to 20 months post last subject dose with a median of 16.7 months follow up for the NSCLC cohort.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dato-DXd_NSCLC | 27/40 (67.5%) | 12/40 (30%) | 38/40 (95%) |
| Dato-DXd_TNBC | 43/79 (54.4%) | 13/79 (16.5%) | 77/79 (97.5%) |
| Event | Dato-DXd_NSCLC | Dato-DXd_TNBC |
|---|---|---|
| PneumoniaInfections and infestations | 2/40 | 6/79 |
| Decreased appetiteMetabolism and nutrition disorders | 3/40 | 0/79 |
| Covid-19Infections and infestations | 0/40 | 2/79 |
| NauseaGastrointestinal disorders | 1/40 | 0/79 |
| VomitingGastrointestinal disorders | 1/40 | 0/79 |
| Gastrointestinal infectionInfections and infestations | 1/40 | 0/79 |
| Pneumonia bacterialInfections and infestations | 1/40 | 0/79 |
| SyncopeNervous system disorders | 1/40 | 0/79 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/40 | 0/79 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/40 | 1/79 |
| Event | Dato-DXd_NSCLC | Dato-DXd_TNBC |
|---|---|---|
| NauseaGastrointestinal disorders | 24/40 | 34/79 |
| StomatitisGastrointestinal disorders | 23/40 | 38/79 |
| AnaemiaBlood and lymphatic system disorders | 23/40 | 20/79 |
| AlopeciaSkin and subcutaneous tissue disorders | 16/40 | 8/79 |
| Neutrophil count decreasedInvestigations | 7/40 | 26/79 |
| VomitingGastrointestinal disorders | 13/40 | 23/79 |
| White blood cell count decreasedInvestigations | 3/40 | 25/79 |
| Weight decreasedInvestigations | 12/40 | 10/79 |
| ConstipationGastrointestinal disorders | 11/40 | 19/79 |
| Decreased appetiteMetabolism and nutrition disorders | 11/40 | 15/79 |
FAS: Enrolled participants who have received at least one dose of treatment.
| Age, Continuous(Year) | Dato-DXd_NSCLC | Dato-DXd_TNBC | Total |
|---|---|---|---|
| Mean | 59.4 ± 9.7 | 50.3 ± 10.2 | 54.85 ± 9.95 |
| Sex: Female, Male(Participants) | Dato-DXd_NSCLC | Dato-DXd_TNBC | Total |
|---|---|---|---|
| Female | 11 | 79 | 90 |
| Male | 29 | 0 | 29 |
| Race (NIH/OMB)(Participants) | Dato-DXd_NSCLC | Dato-DXd_TNBC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 40 | 79 | 119 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Dato-DXd_NSCLC | Dato-DXd_TNBC | Total |
|---|---|---|---|
| China | 40 | 79 | 119 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2022 to primary completion in Nov 2023, 15 months.
Results were first posted in Jun 2025, 1 year 7 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 15 months is below that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Datopotamab deruxtecan
Carcinoma, Non-Small-Cell Lung →